Clinical trial · Interventional
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma
NCT00316420CI-TRIAL-00003239completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capecitabine (Xeloda) | Drug | Capecitabine | ALIAS |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- MTD and DLT for the combination therapy of gemcitabine and capecitabine
- timeFrame
- January 2010
Secondary outcomes (1)
- measure
- Tumor Response
- timeFrame
- January 2010
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic or unresectable pancreatic cancer * No prior chemotherapy except radiation-sensitizing doses of 5-FU * No radiotherapy less than 4 weeks prior to the start of the study Exclusion Criteria: * Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-FU * Moderate to severe renal impairment * Uncontrolled diabetes * Inability to swallow tablets
References
Publications (0)
Data not yet available
No reference posted for this study.